vimarsana.com

Page 10 - இயக்குனர் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

Share this article Share this article LUND, Sweden, April 7, 2021 /PRNewswire/ BioInvent International AB ( BioInvent ) (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808. FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development,  said

Notice to attend the Annual General Meeting of INVISIO

Notice to attend the Annual General Meeting of INVISIO
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Endeavour Silver Signs Definitive Agreement to Sell the El Cubo Mine in Guanajuato, Mexico to

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Endeavour Silver Signs Definitive Agreement to Sell the El Cubo Mine in Guanajuato, Mexico to . Endeavour Silver CorporationMarch 17, 2021 GMT VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) Endeavour Silver Corp. (TSX: EDR, NYSE: EXK) (“Endeavour”) announces that it has signed a definitive agreement to sell the El Cubo mine in Guanajuato, Mexico to VanGold Mining Corp. (“VanGold”) for $15 million in cash and share payments plus up to $3 million in contingent payments (all dollar amounts in USD unless otherwise noted). VanGold will pay $15,000,000 to Endeavour as follows:

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.